The manufacturer of mpox vaccine, Bavarian Nordic, commercially launched the product in April 2024. Jynneos is available for clinics, pharmacies, and health systems to purchase from their usual vaccine distributors. There is no shortage at this time. 

Please check sf.gov/mpox for where vaccine can be obtained.  We recommend calling the location to check availability before going.

Most insurance plans cover the cost of Jynneos vaccination for members who meet CDC eligibility criteria.

CDC eligibility criteria for mpox vaccination have been published. Please note that SFDPH eligibility for mpox vaccine includes additional criteria beyond the CDC criteria.

Jynneos is FDA-approved for adults, to be given via the subcutaneous route.  

An FDA Emergency Use Authorization (EUA) lists two additional indications for Jynneos:

1. Subcutaneous administration in children under 18 years of age.  There is no lower limit to the age of children who can receive Jynneos and the dosage is the same as the adult dose (0.5 mL).
2. Intradermal administration in adults.

Jynneos dosing is generally provided to adults as 0.5mL subcutaneous administration, while 0.1mL intradermal administration remains as a dose-sparing option if product shortages arise. Pediatric dosing is solely via the subcutaneous route. 

If intradermal administration is used, this involves injecting the vaccine superficially between the epidermis and the hypodermis layers of the skin, typically of the volar aspect (inner side) of the forearm. If the volar aspect of the forearm is not an option (e.g., strong patient preference), intradermal administration of vaccine may be performed at the upper back below the scapula or at the deltoid.

See SFDPH minor consent guidance for the process by which minors ages 12 years and older may consent to receive Jynneos vaccine.